PCOS doesn’t disappear at menopause. The 2023 international evidence-based guidelines recognize PCOS as a lifelong condition, meaning the hormonal imbalances, metabolic risks, and visible symptoms like excess hair growth can persist well beyond your reproductive years. What changes is how the condition shows up and which treatments make sense.
After menopause, estrogen levels drop sharply while androgen production stays relatively stable. This shift toward androgen dominance can keep PCOS symptoms active or, in some cases, make them worse. Managing the condition at this stage focuses on three main areas: controlling the metabolic risks that grow more serious with age, treating persistent skin and hair symptoms, and monitoring for conditions that overlap with normal aging.
Why PCOS Persists After Menopause
During your reproductive years, PCOS is defined by a combination of irregular periods, excess androgens, and polycystic ovaries. Menopause eliminates the first marker entirely (periods stop for everyone) and makes ovarian imaging less useful. But the underlying hormonal pattern, particularly elevated androgens, continues. Both clinical signs of excess androgens (visible hair growth, thinning scalp hair, acne) and elevated androgen levels on blood tests persist in postmenopausal women with PCOS.
Lower levels of sex hormone-binding globulin (a protein that keeps androgens in check) after menopause mean more free testosterone circulates in the body. For women with PCOS, this compounds an already-existing imbalance. If you were diagnosed earlier in life, that diagnosis still applies. If you were never formally diagnosed but had a long history of irregular cycles with excess hair growth or other androgen-related symptoms between ages 20 and 40, a clinician can still make the diagnosis retrospectively.
One important distinction: new or suddenly worsening symptoms of excess androgens appearing for the first time after menopause need a thorough workup. Androgen-producing tumors and a condition called ovarian hyperthecosis can mimic PCOS and require different treatment. Your doctor will typically check androgen levels and may order imaging to rule these out.
Managing Excess Hair Growth and Hair Loss
Hirsutism (unwanted facial and body hair) is often the most bothersome symptom that carries over from the reproductive years, and it can worsen after menopause due to that shift toward androgen dominance. Treatment takes at least six months to evaluate, so patience matters.
During the reproductive years, combined oral contraceptive pills are the go-to first-line treatment because they suppress androgen production and can reduce hair growth by 60% to 100%. After menopause, contraceptive pills are generally no longer appropriate, which shifts the strategy toward other options:
- Spironolactone blocks androgen receptors throughout the body. It’s typically started at a low dose and increased as needed, with the most effective range being 100 to 200 mg daily, though lower doses (25 to 100 mg) have fewer side effects. Without the need for contraception concerns, spironolactone becomes a practical standalone option after menopause.
- Finasteride prevents testosterone from converting into its more potent form in the skin. Doses of 2.5 to 5 mg daily have been shown to reduce both hair growth scores and hair shaft diameter with relatively few side effects.
- Topical eflornithine cream (13.9%) slows hair growth by inhibiting cell division in hair follicles. Results typically become visible within 6 to 8 weeks. Combining it with laser hair removal can improve outcomes beyond what either approach achieves alone.
- Mechanical hair removal such as laser treatment or electrolysis addresses existing hair directly, while medications work to slow new growth.
For androgenic hair thinning on the scalp, the same anti-androgen medications can help by reducing the hormonal signal that miniaturizes hair follicles. Topical treatments used for female pattern hair loss may also be considered alongside systemic therapy.
Metabolic Risks That Increase With Age
The metabolic features of PCOS, particularly insulin resistance, don’t resolve at menopause. They layer on top of the metabolic changes that happen with aging naturally. This combination raises the stakes for type 2 diabetes, high blood pressure, and abnormal cholesterol levels.
Insulin resistance is central to PCOS at every age. After menopause, the loss of estrogen’s protective metabolic effects can make insulin resistance worse. If you haven’t already been screened for type 2 diabetes, regular monitoring of blood sugar and insulin markers becomes especially important. Lifestyle interventions, including regular physical activity and dietary changes that improve insulin sensitivity, remain the foundation of metabolic management at this stage. These aren’t just helpful additions; they’re the single most impactful tool for addressing the root metabolic dysfunction.
The cardiovascular picture is nuanced. Women with PCOS do have higher rates of risk factors like hypertension (26% in one study of women with PCOS compared to 21% in controls), but this hasn’t consistently translated into higher rates of heart attacks or other cardiac events in midlife. One study following women to an average age of about 47 found no significant increase in heart attack risk for women with PCOS. Still, the accumulation of risk factors over decades matters, and aggressive management of blood pressure, cholesterol, and blood sugar in your postmenopausal years is the best strategy to keep that risk from catching up.
A Surprising Benefit for Bone Health
Osteoporosis is a major concern for all postmenopausal women, but PCOS appears to offer some protection here. A large population-based study found that women with PCOS have a substantially reduced risk of fractures, particularly in the arms and legs. The risk reduction was about one-third and held up regardless of whether testosterone levels were elevated or normal.
The reasons likely involve several overlapping factors. Higher androgen levels, greater insulin activity, and higher average body weight all promote bone density. However, this protective effect has limits. If insulin resistance progresses to long-standing type 2 diabetes with complications, fracture risk actually increases. So the bone benefit isn’t a reason to ignore metabolic management. It’s another reason to keep diabetes from developing.
Hormone Therapy Considerations
Menopausal hormone therapy (HT) is an option some women with PCOS consider for hot flashes, sleep disruption, and other vasomotor symptoms. The decision involves the same risk-benefit calculation as for any postmenopausal woman, but with a few PCOS-specific considerations. Estrogen therapy can raise sex hormone-binding globulin, which reduces free testosterone and may help with androgen-related symptoms. On the other hand, the metabolic profile in PCOS (higher baseline cardiovascular risk factors, potential insulin resistance) needs to be factored into the decision.
If hormone therapy is appropriate for you, it can serve double duty by addressing both menopausal symptoms and some residual PCOS features. This is a conversation best tailored to your specific risk profile rather than a blanket recommendation.
What Ongoing Monitoring Looks Like
After menopause, PCOS management shifts from reproductive concerns to long-term metabolic surveillance and symptom control. Practical monitoring includes regular screening for type 2 diabetes (especially if you have insulin resistance or prediabetes), lipid panels to track cholesterol, and blood pressure checks. Androgen levels may be checked periodically, particularly if symptoms change or worsen, to ensure nothing else is driving the hormonal imbalance.
Weight management continues to play an outsized role. Even modest weight loss (5% to 10% of body weight) can meaningfully improve insulin sensitivity, androgen levels, and cardiovascular risk markers. The specific approach matters less than consistency. Resistance training is particularly valuable after menopause because it supports both insulin sensitivity and bone density simultaneously.
Mental health screening also deserves attention. Depression and anxiety occur at higher rates in women with PCOS across the lifespan, and the hormonal shifts of menopause can amplify mood changes. If you notice worsening anxiety, low mood, or sleep disruption beyond what you’d expect from menopause alone, it’s worth addressing directly rather than attributing everything to “just menopause.”